Day: September 14, 2026

The Future of Asian Biotech: Bridging the "Valley of Death" | AHA Q1 2026 Recap

What is the state of healthcare investment in 2026? In this special session of the Alliance of Healthcare Investors in Asia (AHA), we convene a closed-door panel of investors, operators, ...and strategics from Singapore, China, Korea, Taiwan, and the US.

The consensus is clear: Biotech is cross-border by default. We break down the shift toward early-stage innovation and how Asia is uniquely positioned to capture value where global capital has traditionally pulled back.

Key Discussion Points:
- Asset Selection: Why "strong science" is only the beginning—how to identify assets that compound in value.
- The "Valley of Death": Capitalizing on the gap in early-stage development while global markets focus on de-risked assets.
- The China-Singapore Pathway: A strategic look at originating IP in China and leveraging Singapore for global translational development.
- Navigating Cross-Border Complexity: Why regulatory and commercial success now requires a multi-geography strategy.

00:00 Introduction: The Future of Asian Biotech
35:31 Keynote: The BlueJay Therapeutics Story (Dr. Keting Chu)
1:11:21 The Funding Shift: Navigating the "Valley of Death"
1:29:46 The Scientist’s Edge: Why Science is the Only Metric
1:40:24 Strategic Corridor: Bridging China and Singapore
2:02:47 Global Regulatory Strategy: Speed vs. Market Size
2:23:13 Regional Market Access: Mutual Recognition & Work Sharing ClosingShow More
The Future of Asian Biotech: Bridging the "Valley of Death" | AHA Q1 2026 Recap
The Future of Asian Biotech: Bridging the "Valley of Death" | AHA Q1 2026 Recap
What is the state of healthcare investment in 2026? In this special ...
Exploring the Boston & Singapore Biomedical Ecosystems: Best Practices and Future Collaborations
Exploring the Boston & Singapore Biomedical Ecosystems: Best Practices and Future Collaborations
The COVID-19 pandemic has significantly accelerated the development of ...